Intra-Cellular Therapies (ITCI) Receives a Buy From RBC Capital
Intra-Cellular Therapies Analyst Ratings
Canaccord Genuity Adjusts Intra-Cellular Therapies Price Target to $113 From $107, Maintains Buy Rating
Intra-Cellular Therapies Analyst Ratings
Intra-Cellular Therapies Analyst Ratings
Intra-Cellular Therapies Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Veeva Systems (VEEV), Intra-Cellular Therapies (ITCI) and Phreesia (PHR)
Buy Rating Affirmed on Intra-Cellular Therapies Amid Strong Sales and Promising Clinical Trials
Analyst Ratings For Intra-Cellular Therapies
RBC Capital Remains a Buy on Intra-Cellular Therapies (ITCI)
Intra-Cellular Therapies Analyst Ratings
Intra-Cellular Therapies: A Hold Rating Amid Anticipation of Critical Phase 3 Data and Diverse Clinical Pipeline
Buy Rating Affirmed: Intra-Cellular Therapies Exceeds Q1 Expectations With Caplyta Sales Surge
Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $120 Price Target
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Intra-Cellular Therapies (ITCI)
Intra-Cellular Therapies Analyst Ratings
Buy Rating on Intra-Cellular Therapies as Caplyta Shows Promise in Major Depressive Disorder Market
Intra-Cellular Therapies Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Thermo Fisher (TMO), Intra-Cellular Therapies (ITCI)
Analysts Conflicted on These Healthcare Names: Intra-Cellular Therapies (ITCI), Eli Lilly & Co (LLY) and Sanofi (OtherSNYNF)